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AMV = age-matched virgin; E+P = estrogen and progesterone; MNU = methylnitroso urea; TDLU = terminal ductal lobular-like structure; TGF =
transforming growth factor; WAP = whey acidic protein.
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Introduction
On the basis of epidemiologic studies and pathology,
breast cancer appears to be an extremely complex, multi-
factorial disease. In spite of our growing understanding of
the molecular aberrations that lead to cancer, and the role
of endocrine signaling pathways in the progression of the
disease, there are few common links pointing to an individ-
ual’s susceptibility to breast cancer. However, one consis-
tent finding is the correlation between the timing of normal
endocrine-related developmental events and breast cancer
risk [1]. In particular, there is strong epidemiologic evi-
dence that women who experience a full-term pregnancy
early in their lives have a significantly reduced risk for devel-
oping breast cancer [2–5]. This has been corroborated by
numerous experimental studies in rodents that resound-
ingly demonstrated the protective effect of an early full-term
pregnancy against mammary tumors (reviewed in [6]). In
addition, hormonal mimicry, by treatment with estrogen and
progesterone (E+P) or human chorionic gonadotropin for a
period of at least 21 days, can be equally effective for
inducing a refractory state that is similar to that afforded by
an early full-term pregnancy [6–13].
The observation that the protective effect of an early full-
term pregnancy can be accurately reproduced in rodents
has lead to the development of defined animal models for
studying this parity-related phenomenon. For many years,
tumor-susceptible rat models were the mainstay of this
experimental effort; however, there is a growing body of evi-
dence suggesting that several strains of mice may also be
appropriate models for these studies. Despite the wealth of
literature supporting the role of endocrine-mediated
processes in parity-related refractoriness, little is known of
the molecular mechanisms that govern pregnancy-specific
developmental changes in the mammary gland. In this com-
mentary, we consider the contributions made by several
recent publications to the advancement of our understand-
ing of the molecular and cell-specific changes apparent in
the parous (protected) gland. In this context, ‘persistent
changes’ are defined as alterations that occur as a result of
parity but that endure far beyond the initial stimulatory event.
Taken together, these findings provide important insights
into the strategies that might be employed for future studies
of this parity-related phenomenon.
A global profile for molecular changes in the
parous mammary gland
As a preliminary step in elucidating the molecular mecha-
nisms that underlie parity-reIated protection, we and others
have searched for molecular changes in the parous
mammary gland. In the first study of this kind [14], we
employed the Wistar–Furth rat model in conjunction with
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suppression subtractive hybridization to isolate molecular
biomarkers for the protective effect of an early full-term
pregnancy. Using this approach, we identified a set of 100
independent (nonredundant) markers that were persistently
upregulated in the glands of 21-day E+P treated (20µg
estrogen/20mg progesterone), 28-day involuted rats, as
compared with age-matched virgin (AMV) control animals.
In an elaborate and rigorously executed study, D’Cruz and
coworkers [15] applied global profiling metholodologies to
examine persistent changes in the pattern of gene expres-
sion, as a function of parity, in the rodent mammary gland.
Using oligonucleotide arrays, they performed a quantita-
tive assessment of the expression levels of 5500 genes in
the mammary glands of parous and nonparous FVB mice.
In addition, they verified the expression of a subset of can-
didate markers by Northern analysis.
One concern raised by this type of analysis is that the find-
ings may not be applicable across different species or
even across different strains of mice [6]. Furthermore,
although the protective effect of parity has been well char-
acterized in many rat models of chemical carcinogenesis,
these studies have only been performed in three strains of
mouse [16,17]. To corroborate their findings, D’Cruz and
coworkers examined the expression profile of a smaller
subset of these markers as a function of parity in the
mammary glands of 129SvEv and Balb/c mice, as well as
Lewis and Sprague–Dawley rats. As a result of this analy-
sis, they identified a subset of 38 genes that exhibited per-
sistent alterations in their pattern of expression in parous
versus nonparous rodents.
Global profiling: a predictive tool for parity-
specific change in mammary gland
To extend their findings, D’Cruz and coworkers [15] tested
whether the expression pattern of this subset of markers
was sufficient to predict, in a blinded manner, the repro-
ductive history of a sample. To examine the predictive merit
of their approach, they performed microarray analysis with
an independent group of mammary gland RNA samples
and then used hierarchical clustering, based on the expres-
sion profiles of their 38 genes, to determine the reproduc-
tive history of the tissues of origin. These results elegantly
demonstrate that this data set can be effectively and repro-
ducibly used as a predictive indicator of parity-specific pro-
tection; such findings raise the prospect of developing a
prognostic tool that is also translational to human studies.
Parity results in changes to growth-regulatory
pathways in rodent mammary gland
D’Cruz and coworkers [15] showed that genes that
encode growth factors such as amphiregulin (A-reg),
pleiotrophin (Ptn), leptin (Ob) and insulin-like growth
factor-1 (Igf-1), which may potentially be involved in epithe-
lial proliferation, are downregulated in the parous involuted
gland. In the case of Ptn and A-reg, at least, downregula-
tion is observed as early as mid-pregnancy (day 12), and
these genes remain persistently downregulated following
21 days of lactation and 28 days of postlactational involu-
tion. Conversely, genes that encode markers of the trans-
forming growth factor (TGF)-β3 signaling pathway are
persistently upregulated following parity and remain ele-
vated (as compared with AMV control animals) for up to
30 weeks following postlactational involution. Previous
studies have shown that TGF-β3 mRNA is markedly upreg-
ulated during involution, reaching peak expression during
the second phase of this process [18]. Therefore, the per-
sistent expression of TGF-β3 observed by D’Cruz and
coworkers could be a function of involution rather than
parity. From our own studies (Ginger M, Rosen J, unpub-
lished observations) we have also observed the downregu-
lation of certain growth-promoting molecules; in contrast,
markers involved in cell cycle control (Cdc42, Rb) or the
modulation of the TGF-β signaling pathway (Fstl-1, Nrln-1)
are upregulated in the parous mammary gland [14]. Inter-
estingly, the observed changes in the level of insulin-like
growth factor-1 mRNA may reflect an alteration in systemic
growth hormone levels reported previously [10]. Alto-
gether, these findings tend to support the notion that there
are persistent changes in growth regulatory pathways in
the parous mammary gland.
The downregulation of mRNA for certain growth-stimula-
tory molecules is a tantalizing observation, in particular Ptn,
Igf-1 and A-reg, because over-expression of these growth
factors has been associated with human breast cancer.
However, these findings alone do not provide sufficient
explanation for the refractory nature of the parous gland
because it has been adequately demonstrated that the
gland can re-enter the proliferative phase during subse-
quent pregnancies. However, as suggested by D’Cruz and
coworkers [15] and previously by Sivaraman and col-
leagues [17], the role of these molecules may only become
evident once the gland is exposed to further proliferative
stimuli. Moreover, it is possible that the downregulation of
growth-promoting molecules and the upregulation of the
TGF-β3 signaling pathway may work in concert with one
another, as well as other factors, to confer an altered
response to subsequent proliferative stimuli.
p53 expression is correlated with a
proliferative block
Previously, Sivaraman and coworkers [9] showed that
one of the earliest consequences of carcinogen expo-
sure is a proliferative burst in the epithelial compartment
of the nonparous gland. In contrast, proliferation is abro-
gated in glands of parous or E+P-treated rats, although
the pathways that govern this differential proliferative
response have not yet been elucidated. In their recent
publication, a potential mechanism for this proliferative
block is explored.194
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Using the Wistar–Furth rat model described in their previ-
ous study [9], those investigators examined the expression
pattern of p53 protein in response to hormonal stimulation
and exposure to the chemical carcinogen methylnitroso
urea (MNU) [17]. Rats aged 45 days were subjected to a
priming dose of estradiol benzoate (to synchronize estrus)
and then treated with E+P (20µg estrogen/20mg proges-
terone, subcutaneously) for a period of 21 days. This rep-
resents a modest dose of hormones, but it is sufficient to
confer 82% protection against MNU-induced tumorigene-
sis. Treatment with E+P induced the upregulation and
nuclear sequestration of p53 protein; p53 was up-regu-
lated as early as 3 days after E+P treatment and remained
elevated for the remainder of the 21-day treatment period.
Strikingly, these levels were persistently elevated 28 days
after hormone withdrawal, as compared with nonparous
AMV, and remained elevated for at least 3 days following
exposure to MNU. Pregnancy induced a similar pattern of
expression; p53 was upregulated during pregnancy,
remained persistently elevated after a 28-day involution
period, and was localized to the nucleus of mammary
epithelial cells. Nuclear accumulation of p53 preceded the
proliferative block described previously and resulted in
transcriptional activation of p53 target genes (MDM2 and
p21CIP1/WAF1) at 3 days post-MNU exposure.
To evaluate the mouse as a suitable model for these
parity-related changes, Sivaraman and coworkers [17]
repeated their experiments using BALB/c mice, and were
able to recapitulate their findings from the E+P-treated
Wistar–Furth rat. Once again, nuclear accumulation of
p53 and induction of p21 preceded the proliferative block
following carcinogen exposure, suggesting that they may
contribute mechanistically to this event. These observa-
tions are strengthened by the finding that p53-mediated
apoptosis, in response to γ-irradiation, in the pregnant and
involuting gland differs significantly from that in the glands
of virgin animals [19]. Given the fact that aberrations in
p53 expression and/or function are often associated with
breast cancer, parity-specific changes in p53 expression
are likely to play an important role in protection against
tumorigenesis.
Pregnancy results in changes in the cellular
composition of the mammary gland
As a consequence of their profiling studies, D’Cruz and
coworkers [15] provided evidence to suggest that there
are persistent alterations in the cellular composition of the
parous mammary gland: the persistent presence of
hematopoietic cells, or cells with heomatopoietic-like prop-
erties, as well as changes in cytokine signaling pathways
within the epithelium. At this point it is not clear whether
the presence of cells with hematopoietic-like properties is
due to the existence of lymphocytes and macrophages
within the gland, or to the recruitment of certain epithelial
cells to express markers of a hematopoietic-like population.
By independent means, Wagner and coworkers [20] also
demonstrated alterations in the epithelial population of the
parous mammary gland. Using double transgenic mice,
expressing Cre-recombinase under the control of the
whey acidic protein (WAP) gene promoter and carrying a
floxed-Stop-lacZ knock-in cassette (Rosa-lox-Stop-lox-
lacZ; hereafter referred to as Rosa-LacZ), those investiga-
tors were able to track the fate of WAP-Cre-expressing
mammary epithelial cells during pregnancy and involution.
The elegance of this approach derives from the ability of
the Cre-recombinase to ‘inscribe’ its effect (i.e. recombi-
nation between loxP sequences), leading to permanent
activation of the lacZ reporter gene in cells in which WAP-
Cre expression has occurred. Thus, any cell that responds
to the appropriate hormonal and developmental signal to
express WAP-Cre retains a lasting signature (β-galactosi-
dase expression) of this developmentally specific event.
Because expression of the WAP-Cre transgene closely
mirrors that of the endogenous WAP gene, hormonal and
developmental changes typical of mid to late pregnancy
are required for its expression. During involution the intri-
cate, differentiated alveolar structure of the epithelium
diminishes through a combination of apoptotic and remod-
eling processes, and the gland regresses to a more quies-
cent state that is similar to that of the mature virgin gland.
WAP gene, and therefore presumably WAP-Cre, expres-
sion ceases during the first few days of involution. However
as Wagner and coworkers [20] demonstrated, a specific
component of the epithelium retains β-galactosidase
expression 3–4 weeks after postlactational involution.
Thus, they identified a novel epithelial cell population origi-
nating from a parity-specific event, but which is distinct
from the majority of the cells in the pregnant mammary
gland. The ability of these cells not only to differentiate but
also to survive involution distinguishes them as a unique
subpopulation of the mammary epithelium. Furthermore,
this observation implies that differentiation alone is not the
basis of their unique properties, but that some other factor
is responsible for their enduring presence in the parous
mammary gland.
Strikingly, these β-galactosidase-expressing cells are con-
fined primarily to the regressed terminal ductal lobular-like
structures (TDLUs in humans) at the extremity of the
ductal tree. As we have previously shown, two markers of
parity-related protection, RbAp46 (a component of the
Sin3A/HDAC, Mi-2/NuRD and histone methyltransferase
complexes) and G.B7 (a noncoding RNA), are likewise
expressed in a localized manner in the TDLU-like struc-
tures of the involuted mammary gland [14].
A unifying hypothesis
Taken together, these findings suggest that there are per-
manent alterations in the epithelial compartment of the195
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Figure 1
Unified model for parity-specific changes in the mammary gland. (a) Summary of reported parity-dependent changes in the mammary gland.
Pregnancy induces multiple changes in the mammary epithelial cells, including nuclear accumulation of p53 and induction of whey acidic protein
(WAP)-Cre expression (and subsequently β-galactosidase expression, indicated by blue cells) in WAP-Cre/Rosa-LacZ mice, and alteration in gene
activity perhaps leading to changes in cell fate. During involution, a large component of the epithelium is eliminated through programmed cell death;
however, a specific subpopulation is able to circumvent this process. The involuted mammary gland is characterized by persistent changes in gene
expression, nuclear localization of p53, and an altered proliferative capacity in response to carcinogen. (b) Potential mechanism for the parity-
specific changes in cell fate: Pregnancy invokes epigenetic changes affecting cell fate in the parous mammary gland. Epigenetic changes may be
induced by a number of mechanisms, including chromatin remodeling, DNA methylation/demethylation, and histone modification, and as a result of
de novo chromatin assembly. RbAp46 is a component of a number of complexes responsible for these processes, including the NuRD complex
[23], which also contains methyl-CpG binding domain proteins (MBD). The common presence of RbAp46 in these complexes might thus provide a
mechanism for sequential shuttling between these different functions, and in addition provides a link between DNA methylation and chromatin
regulation. Noncoding RNAs have also been implicated in these changes in gene expression, through their association with chromatin remodeling,
histone acetylation/deacetylation, and transcription factor complexes, as well as RNA interference [24,25]. Epigenetic changes can regulate cell
fate in a number of ways, for instance by altering gene activity, by providing a signal for survival or proliferation, and by mediating responses to DNA
damage. In addition, it is likely that there is continual cross-talk between the epithelium and the stroma, thus providing an additional level of
epigenetic regulation in the parous mammary gland. Ac, acetylated histones; M, methylated cytosine; TF, transcription factor.
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parous mammary gland (Fig.1a). These changes include,
but are not limited to, the following: an alteration in the sig-
naling pathways governing cell-growth (and possibly also
chemoattractant properties or the expression of
hematopoietic markers); the ability to differentiate, survive
apoptosis, and still retain the propensity for self-renewal;
and the ability to circumvent proliferative stimuli, possibly
through the transcriptional activation of p53 target genes.
These changes endure beyond the primary phase of stim-
ulation due to the hormonal manipulation or pregnancy,
persisting 1 or even 6 months after this initial inductive
event. In addition, changes in systemic hormone levels, as
well as in the mammary stroma [21], may also participate
in the protective effects of an early pregnancy.
How does pregnancy impose such persistent changes on
the mammary gland? Wagner and coworkers [20] sug-
gested that pregnancy confers a ‘functional memory’ on
the mammary epithelium. Sivaraman and colleagues [17]
hypothesized that pregnancy results in changes to the
‘developmental fate’ of a subpopulation of epithelial cells.
Together, these studies suggest that pregnancy alters the
fate of a specific population of epithelial cells, but how is
cell fate altered by pregnancy? We propose that epige-
netic factors might provide a unifying mechanism for this
process (Fig.1b) [14]. Epigenetic factors tell a cell who it
is, where it resides, and what type of function it can
perform. Changes in epigenetic regulation (through the
processes of DNA methylation, histone modification, and
chromatin remodeling) frequently accompany develop-
mental processes, and thus provide a lasting signal that
restricts the pattern of gene expression in those cells, long
after the inductive event has been removed [22]. Such
changes could thus provide an enduring ‘memory’ that
determines cell fate and prevents cell-lineage aberrations
that lead to cancer.
Conclusion
Taken in concert, these studies, as well as our own find-
ings, provide several important conclusions. First, parity
results in persistent changes in the pattern of gene
expression in the rodent mammary gland. Second, the
molecular changes induced by E+P treatment (hormonal
mimicry) are mirrored by similar changes in the parous
gland. Third, the molecular, proliferative, and cell-specific
changes observed in the parous (or E+P-treated) mouse
recapitulate the parity-related alterations seen in the rat.
Fourth, parity results in an altered epithelial population in
the rodent mammary gland. Such conclusions provide
new insights into the strategies we might use to approach
this question in the future and, in particular, they point to a
new experimental model that recognizes the utility of trans-
genic and knockout mice as a complement to the tradi-
tional rat model. Finally, the generality of this model offers
the hope that we can translate these findings to the pre-
vention of human disease, possibly by mimicking these
developmental events pharmacologically for the chemo-
prevention of breast cancer.
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